Exagen Diagnostics Opens Austin Office

Mar 01, 2006, 00:00 ET from Exagen Diagnostics, Inc.

    ALBUQUERQUE, N.M., March 1 /PRNewswire/ -- Exagen Diagnostics, Inc., which
 develops and commercializes genomic marker-based in vitro diagnostic (IVD)
 kits for prognosis and prediction of treatment response, has opened a new
 business office in Austin, Texas. The office, located in the Cielo Building at
 1250 Capital Texas Highway, houses the company's growing sales and customer
 care departments.
     "Having a strong presence in Austin allows Exagen to take advantage of the
 city's biotech labor pool as we move toward commercializing our first
 products," says James McClintic, Exagen CEO. McClintic, along with Exagen
 President and COO Robert Mignatti, formerly ran Austin-based Esoterix, a
 provider of specialty value-added laboratory testing services.
     Exagen's firsts tests predict the risk of breast cancer recurrence using a
 prognostic index so that women at both low and elevated risk of recurrence can
 be identified with high accuracy. The company, which plans to submit its test
 kits to the Food and Drug Administration for clearance later this year, will
 be the first to market a set of genomic markers for breast cancer prognosis.
 In preparation for its upcoming product launch, Exagen is expanding its sales
 and customer care departments with the addition of a new vice president of
 sales, director of customer care, and both technical services and customer
 services professionals to support Exagen's test kits.
     About Exagen Diagnostics, Inc.
     As an emerging leader in the development of prognostic and predictive in
 vitro diagnostic (IVD) kits, Exagen Diagnostics is uniquely able to discover,
 validate and productize small sets of genomic markers for use in oncology,
 infectious disease and other indications. Exagen aims to commercialize IVD
 kits that can be performed by existing diagnostic laboratories and to develop
 tests that accompany the launch of new therapeutics and/or support
 pharmaceutical R&D/Phase IV. For more information, visit

SOURCE Exagen Diagnostics, Inc.